Related Experiment Videos
[Thrombolysis in acute myocardial infarct]
1Abteilung Kardiologie, Kantonsspital, Luzern.
Insights
High-dose thrombolytic therapy significantly reduces acute myocardial infarction mortality. Early treatment within four hours preserves cardiac function, with different agents offering distinct benefits for reperfusion and preventing reocclusion.
Area of Science:
- Cardiology
- Pharmacology
- Emergency Medicine
Context:
- Acute myocardial infarction (AMI) treatment has evolved with intravenous thrombolytic therapy.
- Early intervention within 24 hours of chest pain onset reduces mortality.
Purpose:
- To compare the efficacy of different thrombolytic agents in preserving cardiac performance within four hours of AMI onset.
- To identify optimal agents for early reperfusion, prevention of reocclusion, and recanalization of occluded vessels.
Summary:
- While all thrombolytic agents reduce AMI mortality, their impact on cardiac function varies based on administration time and pharmacological properties.
- Recombinant tissue plasminogen activator (rt-PA) excels at early reperfusion, APSAC at preventing reocclusion, and streptokinase at recanalizing complex thrombi.
- Adjuvant aspirin and heparin therapy are crucial for preventing reocclusion.
Impact:
- Different thrombolytic agents have distinct roles in managing acute myocardial infarction based on their reperfusion and anti-reocclusion profiles.
- Further research is needed on thrombolytic use in unstable angina, pre-hospital administration, optimal dosing, and the role of future antiplatelet drugs.
Abstract:
The introduction of intravenous, high-dose thrombolytic therapy during a brief period has markedly reduced mortality of patients with acute myocardial infarction. While mortality can be reduced by any of the available thrombolytic agents that are applied within the first 24 hours following onset of chest pain, the effects on preservation of cardiac performance which can be achieved following application of thrombolytic therapy within four hours do markedly differ as a consequence of pharmacological properties and rate of early perfusion and patency between different agents. To preserve cardiac performance, rt-PA is the primary candidate to achieve early reperfusion and APSAC the one to prevent reocclusion. In contrast to these, the fibrin-unspecific thrombolytic agent, streptokinase, with its long fibrinolytic activity, seems to be the primary choice to achieve recanalization of vessels occluded by mixed and organized thrombus consisting of platelets and erythrocytes. Of particular importance is, that reocclusion has been prevented by administering an adjuvant therapy of aspirin and heparin. A number of questions are currently being studied and cannot be answered at this date: a) the majority of data does not support the use of a thrombolytic therapy in patients with unstable angina, b) there is no substantial benefit demonstrated in administering thrombolytic therapy prior to transportation of the patient to the hospital, c) the precise dosage of thrombolytic agents and of possible combinations, d) the putative impact of future antiplatelet drugs to further improve late patency.